tbResList Print — EGb 761 Ginkgo biloba-EGb 761

Filters: qv=438, qv2=%, rfv=%

Product

EGb 761 Ginkgo biloba-EGb 761
Description:
<p>
<strong>EGb 761</strong> is a standardized, purified extract of
<em>Ginkgo biloba</em> leaves developed for medicinal use. It is typically
standardized to approximately <strong>22–27% flavone glycosides</strong> and
<strong>5–7% terpene lactones</strong>, including ginkgolides A, B and C and
bilobalide, while potentially undesirable <strong>ginkgolic acids</strong> are
reduced to very low levels. EGb 761 has antioxidant, mitochondrial,
neuroprotective, vasoregulatory, anti-inflammatory and platelet-activating-factor
antagonist effects and has been studied extensively in cognitive impairment,
dementia and Alzheimer’s disease. Reported mechanisms include reduction of
oxidative stress, stabilization of mitochondrial function, modulation of
neurotransmitter signalling, protection against amyloid-β-associated toxicity,
improved cerebral microcirculation and modulation of inflammatory pathways.
EGb 761 is kept separate from generic <em>Ginkgo biloba</em> supplements
because commercial extracts vary substantially in flavonoid, terpene-lactone
and ginkgolic-acid content and are not necessarily pharmacologically equivalent
to the standardized EGb 761 preparation. EGb 761 is kept separate
from isolated ginkgolides, bilobalide and ginkgolic acids
</p>

<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12417213/">high PCA content in EGb 761 may contribute to cognitive benefits</a><br>
bioactive compounds such as terpenoids (Ginkgolides A, B, and C), polyphenols, organic acids, and flavonoids (quercetin, kaempferol, and isorhamnetin). <br>

<a href="https://pubmed.ncbi.nlm.nih.gov/22784423/">EGb 761</a>
is a dry extract from Ginkgo biloba leaves (35–67:1), extraction solvent acetone
60% (w/w). The extract is adjusted to 22.0–27.0% ginkgo flavonoids and 5.0–7.0% terpene lactones,
consisting of 2.8–3.4% ginkgolides A, B, and C and 2.6–3.2% bilobalide and contains less than 5 ppm
ginkgolic acids<br>

<pre>


Table 1. Protective capacity of individual compounds of EGb 761 in brain cells)
COMPOUNDMEAN (SEM) PROTECTION ( % )
(0.5 mg/ml) (percentage recovery after insult)
Ginkgolide A 8.0±1.9∗∗
Ginkgolide B 33.0±11.2∗
Ginkgolide C 8.5±1.6∗∗
Ginkgolide J 37.0±12.2∗
Bilobalide 36.3±7.7∗∗
Flavonoids 56.4±12.7∗∗∗
</pre>

Pathway results for Effect on Cancer / Diseased Cells

Cell Death(tgid=5)

Apoptosis↑, 2,   Casp3↑, 1,  

Transcription & Epigenetics(tgid=7)

other↝, 1,   tumCV↓, 1,  

DNA Damage & Repair(tgid=10)

P53↑, 1,   cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

EMT↓, 1,   p‑ERK↓, 1,   TumCG↓, 2,  

Migration(tgid=13)

E-cadherin↑, 1,   MMP2↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,   TumMeta↓, 1,   Vim↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

HMGB1↓, 1,   NF-kB↓, 2,  

Drug Metabolism & Resistance(tgid=21)

ChemoSen↑, 1,   Dose↝, 4,   eff↑, 1,   selectivity↑, 1,  

Functional Outcomes(tgid=23)

AntiCan↑, 2,   chemoPv↑, 1,   cognitive↑, 1,   QoL↑, 1,   Risk↓, 1,   TumVol↓, 1,  
Total Targets: 28

Pathway results for Effect on Normal Cells

NA, unassigned(tgid=0)

PAF↑, 1,   PAF↓, 1,   Stroke↓, 3,   Tinn↓, 2,  

Redox & Oxidative Stress(tgid=1)

antiOx↑, 4,   i-antiOx↑, 1,   Catalase↑, 1,   GSR↑, 1,   ROS↓, 4,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3)

ATP↑, 2,   MMP↑, 4,  

Cell Death(tgid=5)

Apoptosis↓, 1,   mt-Apoptosis↓, 1,   Bax:Bcl2↓, 1,   Casp3↓, 1,   Casp9↓, 1,  

Transcription & Epigenetics(tgid=7)

other∅, 1,   other↝, 1,   other↑, 1,  

DNA Damage & Repair(tgid=10)

cl‑PARP↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

CD133↑, 1,   GSK‐3β↝, 1,  

Migration(tgid=13)

AntiAg↑, 1,   AntiAg∅, 1,   Ca+2↑, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14)

angioG↓, 1,   angioG↑, 1,   SOX18↑, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15)

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16)

IL6↑, 1,   Inflam↓, 4,  

Synaptic & Neurotransmission(tgid=18)

AChE↓, 1,   NGF↑, 1,  

Protein Aggregation(tgid=19)

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21)

BioAv↑, 1,   Dose↝, 13,   Dose↑, 1,   eff↑, 5,   Half-Life↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22)

BloodF↑, 2,   IL6↑, 1,  

Functional Outcomes(tgid=23)

cognitive↑, 10,   hepatoP↑, 1,   memory↑, 3,   neuroP↑, 6,   toxicity↓, 8,  

Infection & Microbiome(tgid=24)

Sepsis↓, 1,  
Total Targets: 52

Research papers

Year Title Authors PMID Link Flag
2026Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trialsJing-Xuan FengPMC13023401https://pmc.ncbi.nlm.nih.gov/articles/PMC13023401/0
2025Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interferenceSunbeom KwonPMC12417213https://pmc.ncbi.nlm.nih.gov/articles/PMC12417213/0
2025Ginkgo biloba leaf extract EGb 761® for the treatment of various diseases: Overview of systematic reviewsKatrin Pfuhlmann40121884https://pubmed.ncbi.nlm.nih.gov/40121884/0
2025Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trialsMatthias Riepe39895346https://pubmed.ncbi.nlm.nih.gov/39895346/0
2023EGb 761 reduces Ca2+ influx and apoptosis after pentylenetetrazole treatment in a neuroblastoma cell lineIshak Suat OveyPMC10516604https://pmc.ncbi.nlm.nih.gov/articles/PMC10516604/0
2023Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic ReviewJakub HortPMC10041984https://pmc.ncbi.nlm.nih.gov/articles/PMC10041984/0
2020Ginkgo biloba Extract Mechanism Inhibits Hepatocellular Carcinoma through the Nuclear Factor-κB/p53 Signaling PathwayRuike Wang32749126https://pubmed.ncbi.nlm.nih.gov/32749126/0
2020Ginkgo biloba Prevents Oxidative Stress-Induced Apoptosis Blocking p53 Activation in Neuroblastoma CellsFrancesco Di MeoPMC7222193https://pmc.ncbi.nlm.nih.gov/articles/PMC7222193/0
2019Ginkgo Biloba Extract Inhibits Metastasis and ERK/Nuclear Factor kappa B (NF-κB) Signaling Pathway in Gastric CancerZhenhua FuPMC6753842https://pmc.ncbi.nlm.nih.gov/articles/PMC6753842/0
2018Ginkgo biloba extract 761 enhances 5-fluorouracil chemosensitivity in colorectal cancer cells through regulation of high mobility group-box 3 expressionXi ChenPMC6038068https://pmc.ncbi.nlm.nih.gov/articles/PMC6038068/0
2018Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its useKate McKeagePMC6267544https://pmc.ncbi.nlm.nih.gov/articles/PMC6267544/0
2017Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trialVida DemarinPMC5317341https://pmc.ncbi.nlm.nih.gov/articles/PMC5317341/0
2015Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysisMeng-Shan Tan25114079https://pubmed.ncbi.nlm.nih.gov/25114079/0
2015Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementiaMasayuki HashiguchiPMC4729005https://pmc.ncbi.nlm.nih.gov/articles/PMC4729005/0
2015Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular DisordersKevin M NashPMC4640423https://pmc.ncbi.nlm.nih.gov/articles/PMC4640423/0
2014Ginkgo biloba extract (EGb 761) promotes peripheral nerve regeneration and neovascularization after acellular nerve allografts in a rat modelZhaowei ZhuPMC11486258https://pmc.ncbi.nlm.nih.gov/articles/PMC11486258/0
2014Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trialsSerge GauthierPMC4259871https://pmc.ncbi.nlm.nih.gov/articles/PMC4259871/0
2014Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trialS I Gavrilova24633934https://pubmed.ncbi.nlm.nih.gov/24633934/0
2013Pharmacokinetic drug interactions involving Ginkgo bilobaMatthias Unger23865865https://pubmed.ncbi.nlm.nih.gov/23865865/0
2010Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cellsJu Wan Kang19585476https://pubmed.ncbi.nlm.nih.gov/19585476/0
2010Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical PracticeChun ShiPMC2820992https://pmc.ncbi.nlm.nih.gov/articles/PMC2820992/0
2008Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatasesAnja KoltermannPMC6512368https://pmc.ncbi.nlm.nih.gov/articles/PMC6512368/0
2007Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trialChristopher D Gardner17982321https://pubmed.ncbi.nlm.nih.gov/17982321/0
2006Stabilization of Mitochondrial Membrane Potential and Improvement of Neuronal Energy Metabolism by Ginkgo Biloba Extract EGb 761ANNE ECKERThttps://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1352.0230
2001Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemiaK Chandrasekaran11743961https://pubmed.ncbi.nlm.nih.gov/11743961/0
1999EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenationG Du10490280https://pubmed.ncbi.nlm.nih.gov/10490280/0
2024Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer's Dementia: Clinical Trial Systematic ReviewGuilherme Lopes de Oliveira PagottoPMC11201198https://pmc.ncbi.nlm.nih.gov/articles/PMC11201198/0